- Home
- KGEI vs AVIR Comparison
KGEI vs AVIR Comparison
Compare KGEI & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KGEI
- AVIR
- Stock Information
- Founded
- KGEI 2008
- AVIR 2012
- Country
- KGEI United States
- AVIR United States
- Employees
- KGEI N/A
- AVIR N/A
- Industry
- KGEI
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- KGEI
- AVIR Health Care
- Exchange
- KGEI Nasdaq
- AVIR Nasdaq
- Market Cap
- KGEI 254.9M
- AVIR 273.0M
- IPO Year
- KGEI N/A
- AVIR 2020
- Fundamental
- Price
- KGEI $6.14
- AVIR $3.39
- Analyst Decision
- KGEI Strong Buy
- AVIR Hold
- Analyst Count
- KGEI 1
- AVIR 1
- Target Price
- KGEI $11.00
- AVIR $6.00
- AVG Volume (30 Days)
- KGEI 508.9K
- AVIR 413.2K
- Earning Date
- KGEI 08-11-2025
- AVIR 08-06-2025
- Dividend Yield
- KGEI N/A
- AVIR N/A
- EPS Growth
- KGEI 42.32
- AVIR N/A
- EPS
- KGEI 0.57
- AVIR N/A
- Revenue
- KGEI $60,739,000.00
- AVIR N/A
- Revenue This Year
- KGEI $32.19
- AVIR N/A
- Revenue Next Year
- KGEI $33.24
- AVIR N/A
- P/E Ratio
- KGEI $10.71
- AVIR N/A
- Revenue Growth
- KGEI 20.06
- AVIR N/A
- 52 Week Low
- KGEI $2.85
- AVIR $2.46
- 52 Week High
- KGEI $9.89
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- KGEI 43.83
- AVIR 51.38
- Support Level
- KGEI $5.55
- AVIR $3.43
- Resistance Level
- KGEI $6.08
- AVIR $3.83
- Average True Range (ATR)
- KGEI 0.51
- AVIR 0.14
- MACD
- KGEI -0.08
- AVIR -0.04
- Stochastic Oscillator
- KGEI 18.66
- AVIR 15.19
About KGEI Kolibri Global Energy Inc. Common stock
Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. The company derives a majority of its revenue from the United States.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).